Verition Fund Management
BMRN icon

Verition Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Verition Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,600
Closed -$237K – 3347
2024
Q4 		$237K Sell
3,600
-21,500
-86% -$1.44M ﹤0.01% 2898
2024
Q3 		$1.76M Buy
25,100
+21,400
+578% +$1.79M 0.01% 1494
2024
Q2 		$305K Hold
3,700
– – ﹤0.01% 2336
2024
Q1 		$323K Sell
3,700
-143,000
-97% -$12.8M ﹤0.01% 2257
2023
Q4 		$14.1M Buy
146,700
+120,800
+466% +$10.7M 0.11% 158
2023
Q3 		$2.29M Hold
25,900
– – 0.03% 720
2023
Q2 		$2.25M Buy
25,900
+5,500
+27% +$518K 0.03% 634
2023
Q1 		$1.98M Sell
20,400
-20,400
-50% -$2.11M 0.03% 706
2022
Q4 		$4.22M Hold
40,800
– – 0.07% 366
2022
Q3 		$3.46M Buy
+40,800
New +$3.63M 0.04% 608
2022
Q2 		– Sell
-11,200
Closed -$863K – 2389
2022
Q1 		$863K Buy
11,200
+8,600
+331% +$720K 0.01% 1578
2021
Q4 		$230K Buy
+2,600
New +$215K ﹤0.01% 2156
2020
Q3 		– Sell
-13,500
Closed -$1.67M – 1067
2020
Q2 		$1.67M Buy
13,500
+3,200
+31% +$318K 0.05% 268
2020
Q1 		$870K Hold
10,300
– – 0.03% 251
2019
Q4 		$871K Hold
10,300
– – 0.02% 491
2019
Q3 		$694K Buy
+10,300
New +$793K 0.02% 516
2019
Q2 		– Sell
-26,700
Closed -$2.37M – 1075
2019
Q1 		$2.37M Buy
26,700
+1,700
+7% +$158K 0.09% 170
2018
Q4 		$2.13M Buy
+25,000
New +$2.38M 0.15% 120
2015
Q2 		– Sell
-25,000
Closed -$3.12M – 621
2015
Q1 		$3.12M Buy
+25,000
New +$2.65M 0.36% 18

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verition Fund Management's BMRN Position: Q1 2026 in Review

Verition Fund Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 86,600 shares — an estimated $5.15M sold.

Verition Fund Management first reported a position in BMRN in Q2 2013 and held it in 38 quarters. The position peaked at $22M in Q2 2022. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Verition Fund Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 86,600 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $5.15M.
  • Verition Fund Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 38 quarters.
  • Verition Fund Management's BioMarin Pharmaceuticals position peaked at $22M in Q2 2022.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.